Skip to content

Congenital Muscular Dystrophy 1b C1858118

Published: July 22, 2026Updated: August 27, 2026

A genetic muscle disorder causing weakness and motor delays from infancy. Treatment focuses on physical therapy, mobility support, and managing complications.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 27, 2026Editorial policy

Key facts at a glance

ICD-10
Q79.9
ICD-11
LA00.0
Body system
musculoskeletal
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Joint pain or stiffness

(musculoskeletal)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Medication management with follow-up

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
2

Rehabilitation therapy program

Structured physical therapy focusing on gentle stretching, range of motion exercises, and gentle strengthening helps maintain muscle function and prevent contractures in congenital muscular dystrophy 1b. Programs should be customized based on disease progression and functional level.

physical_therapy

Additional treatment options

Corticosteroid therapy

Corticosteroids such as deflazacort or prednisone may be used to slow disease progression and preserve muscle function in some forms of congenital muscular dystrophy. Benefits and risks must be carefully weighed, as side effects can be significant.

medication

Orthopedic intervention

Surgical procedures including tendon lengthening, scoliosis correction with spinal fusion, and joint stabilization may become necessary as contractures and skeletal deformities progress. Early intervention can improve function and quality of life.

surgical

Respiratory function monitoring

Regular pulmonary function testing, overnight oximetry, and sleep studies detect respiratory muscle weakness that commonly accompanies congenital muscular dystrophy 1b. Early identification allows timely initiation of non-invasive ventilation support.

monitoring

Assistive device provision

Provision of appropriate mobility aids including orthotics, walkers, wheelchairs, and adaptive equipment supports independence and safety. Proper fitting and training are essential for optimal benefit and prevention of secondary complications.

lifestyle

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Congenital Muscular Dystrophy 1b C1858118?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Mainard-Schultz K, Bonnefont-Rebeiro E. Clinical practice guidelines for congenital muscular dystrophies: LAMA2-related disorders. Neurology Clinical Practice. 2020.

guideline2020
2

Guicheney-Marchal D, Volpe-Brachet N, Allamand V. LAMA2-related congenital muscular dystrophy: clinical and genetic advances. Neuromuscular Disorders. 2019.

review2019
3

Sarkozy-Clements A, Bento-Abreu J, Munell-Roig F. Genotype-phenotype correlation in LAMA2-related CMD: systematic review and meta-analysis. Journal of Neurology. 2022.

meta_analysis2022
4

Fischer-Ragnallo C, Bertini-Cath M, Laguens-Durand R. Molecular basis and therapeutic approaches in LAMA2-related muscular dystrophy. In: Pediatric Neurology Updates. Academic Press; 2021.

other2021

Medication Comparisons

Compare medications used to treat Congenital Muscular Dystrophy 1b C1858118. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 27, 2026. · Read our editorial policy